Fig. 6
Luteolin reduces HCC proliferation by targeting THOC1 in vivo and enhances the anti-tumor effect of cisplatin. a Tumor growth curve, (b) representative images of tumor, and (c) tumor weight of PLC/PRF/5 cells stably transfected with shTHOC1 or shNC in BALB/c nu/nu mice treated with 50 mg/kg luteolin or saline as control, respectively (one-way ANOVA; **P < 0.01, ***P < 0.001). d immunohistochemistry staining indicates the expressions of THOC1, R-loop, and proliferation markers (PCNA and Ki67) in tumors (one-way ANOVA; ***P < 0.001). e Tumor growth curve, (f) representative images of tumor, and (g) tumor weight of PLC/PRF/5-bearing BALB/c nu/nu mice. Luteolin or cisplatin treatment significantly suppressed tumor growth. Furthermore, luteolin can enhance the antitumor effect of cisplatin (one-way ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001)